319 related articles for article (PubMed ID: 34738981)
1. Patient reported outcomes in systemic vasculitis.
Crawshaw H; Wells M; Austin K; Janagan S; Robson JC
Curr Opin Rheumatol; 2022 Jan; 34(1):33-38. PubMed ID: 34738981
[TBL] [Abstract][Full Text] [Related]
2. Patient Reported Outcomes in Large Vessel Vasculitides.
Robson J; Mackie S; Hill C
Curr Rheumatol Rep; 2021 Jan; 23(2):7. PubMed ID: 33511455
[TBL] [Abstract][Full Text] [Related]
3. The COVID-19 pandemic and ANCA-associated vasculitis - reports from the EUVAS meeting and EUVAS education forum.
Kronbichler A; Geetha D; Smith RM; Egan AC; Bajema IM; Schönermarck U; Mahr A; Anders HJ; Bruchfeld A; Cid MC; Jayne DRW
Autoimmun Rev; 2021 Dec; 20(12):102986. PubMed ID: 34718165
[TBL] [Abstract][Full Text] [Related]
4. OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis.
Robson JC; Tomasson G; Milman N; Ashdown S; Boonen A; Casey GC; Cronholm PF; Cuthbertson D; Dawson J; Direskeneli H; Easley E; Kermani TA; Farrar JT; Gebhart D; Lanier G; Luqmani RA; Mahr A; McAlear CA; Peck J; Shea B; Shea JA; Sreih AG; Tugwell PS; Merkel PA
J Rheumatol; 2017 Oct; 44(10):1529-1535. PubMed ID: 28864650
[TBL] [Abstract][Full Text] [Related]
5. Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire.
Robson JC; Dawson J; Doll H; Cronholm PF; Milman N; Kellom K; Ashdown S; Easley E; Gebhart D; Lanier G; Mills J; Peck J; Luqmani RA; Shea J; Tomasson G; Merkel PA
Ann Rheum Dis; 2018 Aug; 77(8):1157-1164. PubMed ID: 29695498
[TBL] [Abstract][Full Text] [Related]
6. Birmingham vasculitis activity score and the short form 36-item health survey predict current depressive disorders in patients with antineutrophil cytoplasmic antibody-associated vasculitis during the SARS-CoV-2 pandemic.
Yun JD; Lee JH; Pyo JY; Ahn SS; Song JJ; Park YB; Lee SW
Z Rheumatol; 2024 Feb; 83(Suppl 1):222-229. PubMed ID: 35748925
[TBL] [Abstract][Full Text] [Related]
7. Developing a disease-specific patient reported outcome measure to enhance understanding of the lived experiences of ANCA associated vasculitis: A protocol paper.
Floyd L; Dhaygude A; Mitra S; Rowland C
PLoS One; 2024; 19(3):e0298796. PubMed ID: 38451929
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes in vasculitis.
Crawshaw H; Janagan S; Austin K; Baker C; Day J; Robson JC
Best Pract Res Clin Rheumatol; 2023 Mar; 37(1):101829. PubMed ID: 37277246
[TBL] [Abstract][Full Text] [Related]
9. Physicians' perceptions about antineutrophil cytoplasmic antibody-associated vasculitis: an online survey report in the time of the COVID-19 pandemic.
Auanassova A; Yessirkepov M; Zimba O; Gasparyan AY; Joshi M; Agarwal V; Kitas GD; Ahmed S
Clin Rheumatol; 2023 Mar; 42(3):831-837. PubMed ID: 36414862
[TBL] [Abstract][Full Text] [Related]
10. Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Using the OMERACT Process.
Robson JC; Milman N; Tomasson G; Dawson J; Cronholm PF; Kellom K; Shea J; Ashdown S; Boers M; Boonen A; Casey GC; Farrar JT; Gebhart D; Krischer J; Lanier G; McAlear CA; Peck J; Sreih AG; Tugwell PS; Luqmani RA; Merkel PA
J Rheumatol; 2015 Nov; 42(11):2204-9. PubMed ID: 26329344
[TBL] [Abstract][Full Text] [Related]
11. MPO-ANCA-positive Microscopic Polyangiitis Following COVID-19 Infection.
Kawashima S; Kishimoto M; Hibino T; Lee H; Sato Y; Komagata Y; Kaname S
Intern Med; 2022 Feb; 61(4):567-570. PubMed ID: 34840232
[TBL] [Abstract][Full Text] [Related]
12. Updates in cutaneous manifestations of systemic vasculitis.
Elbendary A; Abdel-Halim MRE; Ragab G
Curr Opin Rheumatol; 2022 Jan; 34(1):25-32. PubMed ID: 34690279
[TBL] [Abstract][Full Text] [Related]
13. A case of ANCA-associated vasculitis in a 16-year-old female following SARS-COV-2 infection and a systematic review of the literature.
Bryant MC; Spencer LT; Yalcindag A
Pediatr Rheumatol Online J; 2022 Aug; 20(1):65. PubMed ID: 35964067
[TBL] [Abstract][Full Text] [Related]
14. Increase in the number of new cases of ANCA-associated vasculitis in the COVID-19 vaccine era.
Sato T; Umeda M; Sato S; Michitsuji T; Shimizu T; Koga T; Furuse Y; Kawakami A
Clin Immunol; 2023 Jul; 252():109656. PubMed ID: 37263519
[TBL] [Abstract][Full Text] [Related]
15. Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review.
Monti S; Quinn KA; Christensen R; Jayne D; Langford C; Lanier GE; Mahr A; Pagnoux C; Viðarsdóttir MB; Merkel PA; Tomasson G
Semin Arthritis Rheum; 2020 Dec; 50(6):1314-1325. PubMed ID: 33130459
[TBL] [Abstract][Full Text] [Related]
16. Outcome measures for antineutrophil cytoplasmic antibody-associated vasculitis.
Tomasson G
Curr Opin Rheumatol; 2015 Jan; 27(1):38-44. PubMed ID: 25405826
[TBL] [Abstract][Full Text] [Related]
17. Association of the AAV-PRO questionnaire with established outcome measures in AAV.
Maunz A; Jacoby J; Henes J; Robson JC; Hellmich B; Löffler C
Rheumatology (Oxford); 2024 Jan; 63(1):174-180. PubMed ID: 37129542
[TBL] [Abstract][Full Text] [Related]
18. Anti-neutrophil Cytoplasmic Antibodies (ANCA) as Disease Activity Biomarkers in a "Personalized Medicine Approach" in ANCA-Associated Vasculitis.
Osman MS; Tervaert JWC
Curr Rheumatol Rep; 2019 Dec; 21(12):76. PubMed ID: 31879818
[TBL] [Abstract][Full Text] [Related]
19. Regulatory T cells and systemic vasculitis.
Mirouse A; Cacoub P; Saadoun D
Curr Opin Rheumatol; 2023 Jan; 35(1):25-30. PubMed ID: 36508306
[TBL] [Abstract][Full Text] [Related]
20. Development of ANCA-associated vasculitis followed by SARS-CoV-2 vaccination in a patient with HLA-DRB1*09:01 allele.
Kawamura T; Nakazawa D; Nishio S; Isozaki T; Komatsumoto M; Atsumi T
Mod Rheumatol Case Rep; 2023 Jun; 7(2):426-430. PubMed ID: 36610742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
